266 related articles for article (PubMed ID: 17130524)
1. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5.
Peng X; Jhaveri P; Hussain-Hakimjee EA; Mehta RG
Carcinogenesis; 2007 May; 28(5):1000-7. PubMed ID: 17130524
[TBL] [Abstract][Full Text] [Related]
2. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
3. Regulation of steroid receptor expression by 1alpha-hydroxyvitamin D5 in hormone-responsive breast cancer cells.
Hussain-Hakimjee EA; Mehta RG
Anticancer Res; 2009 Sep; 29(9):3555-61. PubMed ID: 19667148
[TBL] [Abstract][Full Text] [Related]
4. Identification of VDR-responsive gene signatures in breast cancer cells.
Towsend K; Trevino V; Falciani F; Stewart PM; Hewison M; Campbell MJ
Oncology; 2006; 71(1-2):111-23. PubMed ID: 17377416
[TBL] [Abstract][Full Text] [Related]
5. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor expression activates the transcriptional and growth-inhibitory response to retinoids without enhanced retinoic acid receptor alpha expression.
Rosenauer A; Nervi C; Davison K; Lamph WW; Mader S; Miller WH
Cancer Res; 1998 Nov; 58(22):5110-6. PubMed ID: 9823320
[TBL] [Abstract][Full Text] [Related]
7. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5.
Hussain-Hakimjee EA; Peng X; Mehta RR; Mehta RG
Carcinogenesis; 2006 Mar; 27(3):551-9. PubMed ID: 16195238
[TBL] [Abstract][Full Text] [Related]
9. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells.
Banwell CM; MacCartney DP; Guy M; Miles AE; Uskokovic MR; Mansi J; Stewart PM; O'Neill LP; Turner BM; Colston KW; Campbell MJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2004-13. PubMed ID: 16609009
[TBL] [Abstract][Full Text] [Related]
10. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer.
Nakagawa K; Kawaura A; Kato S; Takeda E; Okano T
Carcinogenesis; 2005 Feb; 26(2):429-40. PubMed ID: 15539405
[TBL] [Abstract][Full Text] [Related]
11. 1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation.
Lopes N; Carvalho J; Durães C; Sousa B; Gomes M; Costa JL; Oliveira C; Paredes J; Schmitt F
Anticancer Res; 2012 Jan; 32(1):249-57. PubMed ID: 22213313
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D regulates the phenotype of human breast cancer cells.
Pendás-Franco N; González-Sancho JM; Suárez Y; Aguilera O; Steinmeyer A; Gamallo C; Berciano MT; Lafarga M; Muñoz A
Differentiation; 2007 Mar; 75(3):193-207. PubMed ID: 17288543
[TBL] [Abstract][Full Text] [Related]
13. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells.
Yang L; Yang J; Venkateswarlu S; Ko T; Brattain MG
J Cell Physiol; 2001 Sep; 188(3):383-93. PubMed ID: 11473365
[TBL] [Abstract][Full Text] [Related]
14. [Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].
Rochefort H
C R Seances Soc Biol Fil; 1998; 192(2):241-51. PubMed ID: 9841098
[TBL] [Abstract][Full Text] [Related]
15. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins.
Sumida T; Itahana Y; Hamakawa H; Desprez PY
Cancer Res; 2004 Nov; 64(21):7886-92. PubMed ID: 15520195
[TBL] [Abstract][Full Text] [Related]
16. Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative breast cancer cell lines.
Cordes T; Diesing D; Becker S; Diedrich K; Reichrath J; Friedrich M
Anticancer Res; 2006; 26(4A):2749-53. PubMed ID: 16886687
[TBL] [Abstract][Full Text] [Related]
17. MAPK inhibition by 1alpha,25(OH)2-Vitamin D3 in breast cancer cells. Evidence on the participation of the VDR and Src.
Rossi AM; Capiati DA; Picotto G; Benassati S; Boland RL
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):287-90. PubMed ID: 15225787
[TBL] [Abstract][Full Text] [Related]
18. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
19. Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells.
Pramanik R; Asplin JR; Lindeman C; Favus MJ; Bai S; Coe FL
Cell Immunol; 2004; 232(1-2):137-43. PubMed ID: 15876428
[TBL] [Abstract][Full Text] [Related]
20. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
